Vertex Pharmaceuticals Inc (VRTX)

VRTX (NASDAQ:Drugs)
$93.57
pos +0.00
+0.00%
Today's Range: 92.40 - 94.00 | VRTX Avg Daily Volume: 2,088,800
Last Update: 08/29/14 - 4:00 PM EDT
Volume: 0
YTD Performance: 25.94%
Open: $0.00
Previous Close: $92.80
52 Week Range: $58.06 - $99.74
Oustanding Shares: 238,081,533
Market Cap: 22,093,966,262
6-Month Chart
TheStreet Ratings Grade for VRTX
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 9 10 10
Moderate Buy 0 0 0 0
Hold 5 5 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.71 1.71 1.67 1.67
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -46.63
Price Earnings Comparisons:
VRTX Sector Avg. S&P 500
-46.63 0.00 28.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
28.51% 21.13% 112.90%
GROWTH 12 Mo 3 Yr CAGR
Revenue -20.60 7.45 1.02
Net Income 0.00 -0.09 0.00
EPS 0.00 -0.47 0.00
Earnings for VRTX:
EBITDA -0.15B
Revenue 1.21B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $-0.61 $-0.50 $-2.81 $0.06
Number of Analysts 5 5 9 8
High Estimate $-0.51 $-0.41 $-2.50 $1.87
Low Estimate $-0.73 $-0.60 $-3.25 $-2.03
Prior Year $-0.46 $-0.66 $-1.47 $-2.81
Growth Rate (Year over Year) -31.74% 24.24% -91.38% 102.00%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Jul 9, 2014 | 6:44 AM EDT

Here are several themes that are still working -- and now you can get in at a bargain.

bullishVertex Pharmaceuticals price target upped at UBS

Jun 25, 2014 | 7:41 AM EDT

VRTX raised its number, UBS said. Drivers of upside include price, heterozygotes, and takeout potential. $115 price target and Buy rating. 

bearishVertex downgraded at Wainwright

Jun 25, 2014 | 7:33 AM EDT

VRTX was downgraded from Buy to Neutral, HC Wainwright said. $85 price target. 809 drug still has scientific risks. 

 

By

Timothy Collins

 | Jun 24, 2014 | 2:45 PM EDT

You can always buy these names back.

By

Ed Ponsi

 | May 28, 2014 | 10:30 AM EDT

After a decline, the sector has built a base, and these names are breaking out.

By

Timothy Collins

 | May 22, 2014 | 12:30 PM EDT

Spreads are wide right now, so a patient entry is required. 

By

Robert Moreno

 | Mar 20, 2014 | 2:06 PM EDT

You don't need much conviction to trade these two names.

By

Jim Cramer

 | Jan 30, 2014 | 12:50 PM EST

These types of companies are winners today.

bullishVertex Pharm upgraded at UBS

Jan 6, 2014 | 7:26 AM EST

VRTX was upgraded to Buy from Neutral, UBS said. Driven by confidence that lumicaftor-ivacaftor combination will be successful in 2014 ph3 readouts in cystic fibrosis. $99 price target. 

bearishVertex estimates, target cut at Credit Suisse

Oct 30, 2013 | 7:59 AM EDT

Shares of VRTX now seen reaching $78, according to Credit Suisse. Estimates also reduced, given lower Incivek sales. Neutral rating. 

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.